Leading global law firm Baker McKenzie advised Mithra Pharmaceuticals on its EUR 100 million equity funding from Goldman Sachs International. The arrangement has been entered into for a term of approximately 2 years.

Mithra (Euronext: MITRA) is a listed Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span.

Christophe Maréchal, CFO Mithra Women's Health, commented: "We are very pleased to execute this transaction with Goldman Sachs. This equity financing facility comes on top of existing facilities and fits perfectly with our capital management strategy focusing on financial lines offering us flexibility. It enables us to continue developing our pipeline and delivering on our strategy.”

The Baker McKenzie team advising Mithra consisted of lawyers from the Firm’s Brussels and London offices, led by Roel Meers (Partner, Corporate Finance), and included Matthew Dening (Partner, Banking & Finance), Arnaud Flamand (Associate, Corporate Finance) and Megan Schellinger (Partner, Corporate Finance). 

Speaking after the announcement, Roel Meers said, “We were delighted to advise Mithra on successfully securing this important equity funding facility. Mithra is playing an important role innovating and driving change in the Women's Health sector, improving the lives of women. We are honored to be part of the company's journey."

Baker McKenzie previously advised Mithra on its landmark license agreement with Mayne Pharma in 2019 to commercialize its first estetrol-based product, Estelle® in the US, a novel combined oral contraceptive that received FDA approval in 2021. The team also advised Mithra on previous equity and equity-linked funding, including Mithra's EUR 125 million convertible loan.
Explore Our Newsroom